The FDA slapped a boxed warning on Turalio after Daiichi saw liver toxicity in phase 3. There was no evidence of cholestatic ...

▎药明康德内容团队编辑  皮肤没长什么东西，却莫名其妙地反复瘙痒，在夜晚格外严重，甚至痒得睡不着觉；身上挠出一道道印子，用了很多护肤品、止痒药也没什么效果……对于很多肝胆疾病导致胆汁淤积的患者来说，这样难以忍受的全身性瘙痒常常发生，极大地影响了生活质 ...

FOSTER CITY, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported ...

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) received breakthrough therapy designation for its drug candidate in treating cholestatic pruritus in PBC, highlighting its potential effectiveness. The company ...

(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in ...

Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose ...

Report Ocean has published a new report on the Pruritus Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight ...